SMARCA4 was found to be mutated in approximately 19% of lung cancer cell lines evaluated, and most of these mutations were loss-of-function mutations82, indicating that SMARCA4 functions as a tumor suppressor in lung cancer. Here, SMARCA4 is linked to neoplasm.